読み込み中
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
前日終値
$8.60
−$0.41 · -4.55%
日中の時刻はETです。市場データは遅延する場合があります。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日中レンジ
現在 $8.60
52週レンジ
現在 $8.60
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
39
割高
センチメント
62
強気
リスク
66
高リスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
日中レンジ
現在 $8.60
52週レンジ
現在 $8.60
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 1318.5万 USD | — | 449.01万 USD | 485.37万 USD | 146.85万 USD |
| 売上原価 | 6.27万 USD | — | 9.76万 USD | 41.85万 USD | 21.75万 USD |
| 粗利益 | 1312.24万 USD | — | 439.25万 USD | 443.52万 USD | 125.09万 USD |
| 研究開発 | 1236.89万 USD | 1489.85万 USD | 2240.04万 USD | 2263.06万 USD | 2132.74万 USD |
| 販売・一般管理 | 948.44万 USD | 780.93万 USD | 1227万 USD | 1529.08万 USD | 1651.19万 USD |
| 営業費用 | 2185.33万 USD | 1745.99万 USD | 2688.86万 USD | 3689.41万 USD | 3783.94万 USD |
| 受取利息 | 29.71万 USD | — | — | — | — |
| 支払利息 | 6726 USD | 1.5万 USD | 1.71万 USD | 2万 USD | 2.97万 USD |
| 減価償却費と償却費 | 6.27万 USD | 25.89万 USD | 33.91万 USD | 28.83万 USD | 12.67万 USD |
| 営業利益 | −866.83万 USD | −1745.99万 USD | −2249.61万 USD | −3245.89万 USD | −3658.84万 USD |
| 純利益 | −837.79万 USD | −1730.73万 USD | −2973.61万 USD | −2403.67万 USD | −3619.83万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
